+Cdk6 and Cdk6 -/-cells. Protein-DNA complexes were immunoprecipitated using antibodies specific for the indicated histone modification. ChIP and input DNA were analysed by qPCR for the presence of a Vegf-A promoter sequence (region 1 in Supplementary Figure 11c) . The relative enrichment of the histone modification was determined by dividing the percentage of precipitated DNA of the Vegf-A promoter region (ChIP/input) by the percentage of precipitated DNA at a positive control region (ChIP/input). A Tbp promoter region was used as positive control for H3K9ac, H3K4me2 and H3K4me3 and a Neurog1 promoter region was used for H3K27me3. The mean + S.E.M. of two independent experiments is shown. K) H3K36me3 ChIP assays were performed using Cdk6 +/+ and Cdk6high cells. Protein-DNA complexes were immunoprecipitated using an antibody specific for H3K36me3. ChIP DNA was analysed by qPCR for the presence of Vegf-A sequences depicted in the lower panel [black rectangles; middle of the amplicon relative to the TSS (arrow symbol marked +1) of Vegf-A: 1 -386 bp, 2 +693 bp, 3 +2710 bp, 4 +6461 bp, 5 +8621 bp]. The relative enrichment of the histone modification was determined by dividing the percentage of precipitated DNA of the given Vegf-A region (ChIP/input) by the percentage of precipitated DNA of a Gapdh gene region (ChIP/input). The mean + S.E.M. of two independent experiments is shown. L) Human CDK6 and VEGF-A mRNA levels of several human B-cell lines (JVM2, SUP-B15, DOHH2, RAJI, Granta519, U931, SD1, REC1, Ramos RL-7) were analysed by qPCR. The correlation between CDK6 and VEGF-A is depicted in a x,y blot. M) Human CDK6 and VEGF-A mRNA levels of several human T-cell lines (Molt13, HSB2, MKB1, PEER, LBL, HPB-ALL, CCRF, Mac2A, Jurkat, Karpas, Sudhl1, Molt4) were analysed by qPCR. The correlation between CDK6 and VEGF-A is depicted in a x,y blot. N) Human CDK4 and VEGF-A mRNA levels of several human B-cell lines (JVM2, SUP-B15, DOHH2, RAJI, Granta519, U931, SD1, REC1, Ramos RL-7) were analysed by qPCR. The correlation between CDK4 and VEGF-A is depicted in a x,y blot. O) Human CDK4 and VEGF-A mRNA levels of several human T-cell lines (Molt13, HSB2, MKB1, PEER, LBL, HPB-ALL, CCRF, Mac2A, Jurkat, Karpas, Sudhl1, Molt4) were analysed by qPCR. The correlation between CDK4 and VEGF-A is depicted in a x,y blot. Error bars indicate the mean ± SEM. 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES Cell culture, infection of foetal liver cells and expression vectors
Tissue culture conditions, virus preparation, infections establishment of cell-lines and colony forming assays were performed as described previously (Kollmann et al., 2011a ). Expression vectors: pMSCV-puro, pMSCV-Cdk6-puro, pMSCV-Cdk6R31C-puro (Grossel et al., 1999 ), pMSCV-Cdk6K43M-puro (Zacharek et al., 2005 , pMSCV-Cdk4-puro, pMSCV-JunB-puro and pMSCV-cJun-puro.
BCR-ABL -transformed cell lines and Cyclin D1/2/3 -/-MEFs have been described previously (Hoelbl et al., 2010; Kollmann et al., 2011a; Kozar et al., 2004) .
Generation of p185 BCR-ABL -transformed Cdk6 -/-cells with inducible expression of CDK6:
To generate cell lines with doxycycline-inducible expression of CDK6, p185
BCR-ABL -transformed Cdk6 -/-cells were retrovirally transduced with pRevTet-On (Clontech) and selected with puromycin (2 g/ml). To test for doxycycline-inducible gene expression, Cdk6
-/--tet-on cells were transduced with the pRevTRE vector (Clontech) containing a GFP cDNA and selected by growing in hygromycin (400 g/ml). Single cell clones were generated by FACS sorting and screened for clones with the highest doxycyline-dependent induction of GFP and the lowest background expression. These Cdk6 -/--tet-on cells were than transduced with the pRevTRE-tight vector (Clontech) containing CDK6 cDNA and selected by growing in hygromycin (400 g/ml). Expression of CDK6 was induced by addition of doxycycline (0.3-10 g/ml) (Mayerhofer et al., 2008) . 
Isolation of untransformed human B and T cells:

Isolation of untransformed murine B and T cells:
Bone marrow of three 6 week-old C57BL/6J mice was pooled and stained with fluorescence-conjugated antibodies CD3ε and CD19. 4-way purity FACS sorting was performed using an eight-colour BD FACSAria equipped with 488, 633, 546 and 407 nm lasers
[H]-thymidine incorporation and flow cytometric analysis
3 [H]-thymidine incorporation and cell cycle analysis were performed as previously described (Kollmann et al., 2011a) .
Colony forming assay
A defined number of p185 BCR-ABL -transformed cells were plated in growth factor-free methylcellulose (StemCell Technologies). Formed colonies were analyzed after 5 days of incubation by colony counting per dish and taking pictures. Assay was performed in duplicates.
Transplantation of tumour cells into Rag2 -/-and Nu/Nu mice
Tail vein injection and subcutaneous injection were performed as described previously (Kollmann et al., 2011a) .
PD0332991 treatment:
3 Western Blot and qPCR: 1x10 6 cells were incubated with 0, 30, 100, 300, 1000, 3000 nM PD0332991 for 24h, harvested and analyzed .
Protein analysis and immunoblotting
Cell lysates and immunoblotting was performed as described previously (Kollmann et al., 2011a) .
Co-immunoprecipitation: 1000 µg of cell lysates were incubated with 2µg of antibody on a rotating wheel at 4°C overnight, followed by 1/2 hour of incubation in the presence of equilibrated protein A sepharose beads on a rotating wheel at 4°C. After washing 4x the mixture was centrifuged and SDS loading buffer added. Heating the samples for 5 min. at 95°C separated beads and proteins. Reaction mixtures were run on a SDS polyacrylamide gel.
Treatment with bortezomib and cycloheximide: 5 x 10 6 cells were seeded in either 10nM bortezomib, 1µM cycloheximide or a combination of these drugs. After 4h incubation immunoblot analysis was performed.
manufacturer´s recommendations.
RNA-isolation and qPCR analysis
RNA was isolated using TriZol (Invitrogen (v/v) Triton X-100, 100 µg ml -1 RNAse) and incubated at 37 °C for 30 min before measurement via FACS. For evaluation of proliferation rate, 5 x 10 6 cells were stained with CFSE using the CellTrace CFSE Proliferation Kit (Invitrogen) and CFSE-MFI was measured over 20 h. To evaluate the onset of apoptosis, 5 x 10 6 cells were stained with propidium iodide and an APC-conjugated antibody to annexinV (BD Bioscience) and analyzed using a FACS device.
Methylation-specific PCR (MSP):
Methylation-specific PCR was performed as described previously (Kollmann et al., 2011b) .
Immunohistochemistry
Tissue array technology was applied to compare samples using antibodies against CDK6 (sc-untransformed cells. Normal lymph nodes were used as controls.
Human CD31 immunhistochemistry was performed on whole tissue sections. CD31 (JC70A, Dako) -ABC kit: AEC according to the manufacturers recommendations.
Immunofluorescence staining for blood vessels was performed using an antibody against murine CD31 (DIA310, Dianova) and as fluorocrome Alexa Fluor ® 594 ( A11007, Molecular Probes ).
Image Acquisition and Protein Quantification in vivo
Samples were analysed with a Zeiss AxioImager Z1 microscope system with CCD camera and an automated acquisition system TissueFAXS TM (TissueGnostics GmbH). The percentages of Ki-67-, CDK6-, p16
INKa -or CD30-positive cells were depicted as scattergrams. Pictures were digitalized, analysed and quantified. Statistical analysis was performed using HistoQuest TM software (TissueGnostics GmbH, Vienna, Austria).
Vessel density of human tissue samples: Vessel density was assessed by two independent observers. CD31 immunostained sections were scanned (Aperio technologies).
Hot spots of vessel density were determined at low magnification (40x). Each CD31-stained lumen within this hot spot was counted at a magnification of 200x in an area of 0, 25 mm2 by two independent pathologists. Vessel density was prescribed as mean values of counting results.
Immunoflourescence Analysis
IF-Analyses were performed on whole tissue sections of 8 human ALCL cases. Tissue sections were deparaffinized, antigen retrieval was carried out by steamer in TE-buffer. Non specific binding sites were saturated by goatserum for 15 minutes at room temperature. The primary antibodies CDK6 (1: 50 dilution; Sigma-Aldrich, AB-13, SAB4300595) and p16
